Top

Published in:

01-10-2020 | PRECLINICAL STUDIES

Anticancer activity of Turkish marine extracts: a purple sponge extract induces apoptosis with multitarget kinase inhibition activity

Authors: Halil I. Ciftci, Mustafa Can, Doha E. Ellakwa, Salih C. Suner, Mohamed A. Ibrahim, Ayhan Oral, Nazim Sekeroglu, Barış Özalp, Masami Otsuka, Mikako Fujita, Mustafa Alparslan, Mohamed O. Radwan

Published in: Investigational New Drugs | Issue 5/2020

Summary

Marine natural products have drawn a great deal of attention as a vital source of new drugs for the last five decades. However, marine organisms in the seas surrounding Turkey (the Black Sea, the Aegean Sea and the Mediterranean Sea) haven’t been yet extensively explored. In the present study, three marine organisms (Dysidea avara, Microcosmus sabatieri and Echinaster sepositus) were sampled from the Dardanelles (Turkish Straits System, Western Turkey) by scientific divers, transferred to the laboratory and then were extracted with 70% ethanol. The extracts were tested for their cytotoxic effect against K562, KMS-12PE, A549, and A375 cancer cell lines. The sponge extract elicited the most promising cytotoxic activity, thus it was further evaluated against H929, MCF-7, HeLa, and HCT116 cancer cells. Most of the designated cells showed a considerable sensitivity for the sponge extract particularly H929, K562, KMS-12PE and HeLa cells with IC₅₀ less than 10 μg/mL. On the contrary, the other two extracts exhibited no cytotoxic activity on all cells at 100 μg/mL concentration. The sponge extract was tested for its capacity to induce apoptosis in cancer cells and to inhibit a panel of tyrosine kinases showing remarkable results. The outcome of this study represents a platform for discovery of new chemotherapeutic agents of marine natural origin.

Nasr H, Abdel-Aziz M, Radwan M, Shaaban M (2015) Bioactive secondary metabolites from terrestrial Streptomyces baarnensis MH4. Br J Pharma Res 5:72–81. https://doi.org/10.9734/BJPR/2015/14074CrossRef

Zhang C, Liu Y (2015) Targeting cancer with sesterterpenoids: the new potential antitumor drugs. J Nat Med 69:255–266. https://doi.org/10.1007/s11418-015-0911-yCrossRefPubMedPubMedCentral

Radwan MO, Ismail MAH, El-Mekkawy S et al (2016) Synthesis and biological activity of new 18β-glycyrrhetinic acid derivatives. Arab J Chem 9:390–399. https://doi.org/10.1016/j.arabjc.2013.06.032CrossRef

Aung T, Qu Z, Kortschak R, Adelson D (2017) Understanding the effectiveness of natural compound mixtures in Cancer through their molecular mode of action. Int J Mol Sci 18:656. https://doi.org/10.3390/ijms18030656CrossRefPubMedCentral

Ibrahim M, El-Alfy A, Ezel K et al (2017) Marine Inspired 2-(5-Halo-1H-indol-3-yl)-N,N-dimethylethanamines as Modulators of Serotonin Receptors: An Example Illustrating the Power of Bromine as Part of the Uniquely Marine Chemical Space. Marine Drugs 15:248. https://doi.org/10.3390/md15080248CrossRefPubMedCentral

Pujiastuti DY, Ghoyatul Amin MN, Alamsjah MA, Hsu J-L (2019) Marine organisms as potential sources of bioactive peptides that inhibit the activity of angiotensin I-converting enzyme: a review. Molecules 24:2541. https://doi.org/10.3390/molecules24142541CrossRefPubMedCentral

Zhang H, Dong M, Chen J et al (2017) Bioactive secondary metabolites from the marine sponge genus Agelas. Marine Drugs 15:351. https://doi.org/10.3390/md15110351CrossRefPubMedCentral

Heydari H, Gozcelioglu B, Konulugil B (2019) Biodiversity and secondary metabolites of marine sponges from Turkey. Rec Nat Prod 13:367–378. https://doi.org/10.25135/rnp.118.18.07.340CrossRef

Shinde P, Banerjee P, Mandhare A (2019) Marine natural products as source of new drugs: a patent review (2015–2018). Exp Opin Ther Patents 29:283–309. https://doi.org/10.1080/13543776.2019.1598972CrossRef

10.

Liang X, Luo D, Luesch H (2019) Advances in exploring the therapeutic potential of marine natural products. Pharmacol Res 147:104373. https://doi.org/10.1016/j.phrs.2019.104373CrossRefPubMedPubMedCentral

11.

Newman D, Cragg G (2014) Marine-sourced anti-Cancer and Cancer pain control agents in clinical and late preclinical development. Marine Drugs 12:255–278. https://doi.org/10.3390/md12010255CrossRefPubMedPubMedCentral

12.

Skropeta D, Pastro N, Zivanovic A (2011) Kinase inhibitors from marine sponges. Marine Drugs 9:2131–2154. https://doi.org/10.3390/md9102131CrossRefPubMedPubMedCentral

13.

Chakraborty C, Hsu C-H, Wen Z-H, Lin C-S (2009) Anticancer drugs discovery and development from marine organisms. Curr Top Med Chem 9:1536–1545. https://doi.org/10.2174/156802609789909803CrossRefPubMed

14.

Cooper EL, Yao D (2012) Diving for drugs: tunicate anticancer compounds. Drug Discov Today 17:636–648. https://doi.org/10.1016/j.drudis.2012.02.006CrossRefPubMed

15.

Molinski TF, Dalisay DS, Lievens SL, Saludes JP (2009) Drug development from marine natural products. Nat Rev Drug Discov 8:69–85. https://doi.org/10.1038/nrd2487CrossRefPubMed

16.

Mehbub M, Lei J, Franco C, Zhang W (2014) Marine sponge derived natural products between 2001 and 2010: trends and opportunities for discovery of bioactives. Marine Drugs 12:4539–4577. https://doi.org/10.3390/md12084539CrossRefPubMedPubMedCentral

17.

Takamatsu S (2018) Naturally occurring cell adhesion inhibitors. J Nat Med 72:817–835. https://doi.org/10.1007/s11418-018-1220-zCrossRefPubMedPubMedCentral

18.

Anuradha V, Byju K, Emilda R, Anu G, Nair SM, Chandramohanakumar N, Peter KJP, Kumar TRG, Vasundhara G (2013) In silico biological activity of steroids from the marine sponge Axinella carteri. Med Chem Res 22:1142–1146. https://doi.org/10.1007/s00044-012-0119-6CrossRef

19.

Çelenk FG, Özkaya AB, Sukatar A (2016) Macroalgae of Izmir gulf: Dictyotaceae exhibit high in vitro anti-cancer activity independent from their antioxidant capabilities. Cytotechnology 68:2667–2676. https://doi.org/10.1007/s10616-016-9991-0CrossRefPubMedPubMedCentral

20.

Dogan E, Demir O, Sertdemir M, et al (2018) Screening of the selected marine sponges from the coasts of Turkey for antimicrobial activity. Indian J Geo-Mar Sci

21.

Özalp HB, Alparslan M (2016) Scleractinian diversity in the Dardanelles and Marmara Sea (Turkey): morphology, ecology and distributional patterns. Oceanol Hydrobiol Stud 45:259–285. https://doi.org/10.1515/ohs-2016-0023CrossRef

22.

Özalp HB, Caroselli E, Raimondi F, Goffredo S (2018) Skeletal growth, morphology and skeletal parameters of a temperate, solitary and zooxanthellate coral along a depth gradient in the Dardanelles (Turkey). Coral Reefs 37:633–646. https://doi.org/10.1007/s00338-018-1687-9CrossRef

23.

Altıntop M, Ciftci H, Radwan M et al (2017) Design, synthesis, and biological evaluation of novel 1,3,4-Thiadiazole derivatives as potential antitumor agents against chronic Myelogenous leukemia: striking effect of Nitrothiazole moiety. Molecules 23:59. https://doi.org/10.3390/molecules23010059CrossRefPubMedCentral

24.

Dagenais GR, Leong DP, Rangarajan S et al (2019) Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study. Lancet. https://doi.org/10.1016/S0140-6736(19)32007-0

25.

Sever B, Altıntop MD, Radwan MO, Özdemir A, Otsuka M, Fujita M, Ciftci HI (2019) Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors. Eur J Med Chem 182:111648. https://doi.org/10.1016/j.ejmech.2019.111648CrossRefPubMed

26.

Ali TFS, Ciftci HI, Radwan MO et al (2019) New SIRT2 inhibitors: Histidine-based bleomycin spin-off. Bioorg Med Chem. https://doi.org/10.1016/j.bmc.2019.03.003

27.

Radwan MO, Ciftci HI, Ali TFS et al (2019) Antiproliferative S-Trityl-l-cysteine -derived compounds as SIRT2 inhibitors: repurposing and solubility enhancement. Molecules 24:3295. https://doi.org/10.3390/molecules24183295CrossRefPubMedCentral

28.

Ciftci HI, Radwan MO, Ozturk SE et al (2019) Design, synthesis and biological evaluation of Pentacyclic Triterpene derivatives: optimization of anti-ABL kinase activity. Molecules 24:3535. https://doi.org/10.3390/molecules24193535CrossRef

29.

Shida W, Tateishi H, Tahara Y et al (2019) Antileukemic activity of twig components of Caucasian beech in Turkey. Molecules 24:3850. https://doi.org/10.3390/molecules24213850CrossRefPubMedCentral

30.

Bayrak N, Yıldırım H, Yıldız M et al (2020) A novel series of chlorinated plastoquinone analogs: design, synthesis, and evaluation of anticancer activity. Chemical Biology & Drug Design cbdd.13651. https://doi.org/10.1111/cbdd.13651

31.

Ciftci HI, Bayrak N, Yıldırım H et al (2019) Discovery and structure–activity relationship of plastoquinone analogs as anticancer agents against chronic myelogenous leukemia cells. Arch Pharm 352:1900170. https://doi.org/10.1002/ardp.201900170CrossRef

32.

Bayrak N, Yıldırım H, Yıldız M, Radwan MO, Otsuka M, Fujita M, Tuyun AF, Ciftci HI (2019) Design, synthesis, and biological activity of Plastoquinone analogs as a new class of anticancer agents. Bioorg Chem 92:103255. https://doi.org/10.1016/j.bioorg.2019.103255CrossRefPubMed

33.

Ciftci HI, Ozturk SE, Ali TFS, Radwan MO, Tateishi H, Koga R, Ocak Z, Can M, Otsuka M, Fujita M (2018) The first Pentacyclic Triterpenoid Gypsogenin derivative exhibiting anti-ABL1 kinase and anti-chronic Myelogenous leukemia activities. Biol Pharm Bull 41:570–574. https://doi.org/10.1248/bpb.b17-00902CrossRefPubMed

34.

Lee RH, Slate DL, Moretti R, Alvi KA, Crews P (1992) Marine sponge polyketide inhibitors of protein tyrosine kinase. Biochem Biophys Res Commun 184:765–772. https://doi.org/10.1016/0006-291X(92)90656-6CrossRefPubMed

35.

Yoo H-D, Leung D, Sanghara J et al (2003) Isoarenarol, a new protein kinase inhibitor from the marine sponge Dysidea arenaria. Pharm Biol 41:223–225. https://doi.org/10.1076/phbi.41.4.223.15679CrossRef

36.

Bilalis A, Pouliou E, Roussou M et al Increased expression of platelet derived growth factor receptor β on trephine biopsies correlates with advanced myeloma. J BUON 22:1032–1037

37.

Ribatti D, Vacca A (2018) New insights in anti-angiogenesis in multiple myeloma. Int J Mol Sci 19:2031. https://doi.org/10.3390/ijms19072031CrossRefPubMedCentral

38.

Wadleigh M, DeAngelo DJ, Griffin JD, Stone RM (2005) After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies. Blood 105:22–30. https://doi.org/10.1182/blood-2003-11-3896CrossRefPubMed

39.

Gars E, McGee CS, Bosse RC et al (2010) Acute myeloid leukemia cells depend on VEGF, PDGFR and SCF receptor signaling: leukemia regression with Pazopanib. Blood 116:1057–1057. https://doi.org/10.1182/blood.V116.21.1057.1057CrossRef

40.

Lu L, Zhao T-T, Liu T-B, Sun WX, Xu C, Li DD, Zhu HL (2016) Synthesis, molecular modeling and biological evaluation of 4-Alkoxyquinazoline derivatives as novel inhibitors of VEGFR2. Chem Pharm Bull 64:1570–1575. https://doi.org/10.1248/cpb.c16-00386CrossRefPubMed

Title: Anticancer activity of Turkish marine extracts: a purple sponge extract induces apoptosis with multitarget kinase inhibition activity
Authors: Halil I. Ciftci
Mustafa Can
Doha E. Ellakwa
Salih C. Suner
Mohamed A. Ibrahim
Ayhan Oral
Nazim Sekeroglu
Barış Özalp
Masami Otsuka
Mikako Fujita
Mustafa Alparslan
Mohamed O. Radwan
Publication date: 01-10-2020
Publisher: Springer US
Published in: Investigational New Drugs / Issue 5/2020
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-020-00911-8

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Image Credits

ASCO 2024 | Highlights of the Day: Breast cancer – metastatic/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Gynecologic Cancer/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Breast Cancer – local/regional/adjuvant/© 2024 American Society of Clinical Oncology, all rights reserved., Melanoma/© selvanegra / Getty Images / iStock, Antibody drug conjugated with cytotoxic payload/© Love Employee / Getty images / iStock

2024 ASCO Annual Meeting

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 5/2020

Patient selection for a developmental therapeutics program using whole genome and Transcriptome analysis

Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteers

Metabolomic profiling to evaluate the efficacy of proxalutamide, a novel androgen receptor antagonist, in prostate cancer cells

Combating atherosclerosis with targeted Diosmin nanoparticles-treated experimental diabetes

Novel Bacillus strains from the human gut exert anticancer effects on a broad range of malignancy types